Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Werewolf Therapeutics (HOWL) Equity Average (2021 - 2025)

Werewolf Therapeutics (HOWL) has disclosed Equity Average for 5 consecutive years, with $35.5 million as the latest value for Q3 2025.

  • On a quarterly basis, Equity Average fell 63.25% to $35.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was $35.5 million, a 63.25% decrease, with the full-year FY2024 number at $92.4 million, down 20.94% from a year prior.
  • Equity Average was $35.5 million for Q3 2025 at Werewolf Therapeutics, down from $49.4 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $175.4 million in Q3 2021 to a low of $13.9 million in Q2 2021.
  • A 5-year average of $106.1 million and a median of $115.0 million in 2023 define the central range for Equity Average.
  • Peak YoY movement for Equity Average: soared 868.13% in 2022, then tumbled 63.25% in 2025.
  • Werewolf Therapeutics' Equity Average stood at $161.0 million in 2021, then decreased by 21.36% to $126.6 million in 2022, then decreased by 11.63% to $111.9 million in 2023, then decreased by 27.28% to $81.4 million in 2024, then plummeted by 56.33% to $35.5 million in 2025.
  • Per Business Quant, the three most recent readings for HOWL's Equity Average are $35.5 million (Q3 2025), $49.4 million (Q2 2025), and $65.3 million (Q1 2025).